schliessen

Filtern

 

Bibliotheken

Chinese proprietary herbal medicine listed in 'China national essential drug list' for common cold: a systematic literature review

Chinese proprietary herbal medicines (CPHMs) have long history in China for the treatment of common cold, and lots of them have been listed in the 'China national essential drug list' by the Chinese Ministry of Health. The aim of this review is to provide a well-round clinical evidence assessment on... Full description

Journal Title: PLoS ONE 01 January 2014, Vol.9(10), p.e110560
Main Author: Wei Chen
Other Authors: George Lewith , Li-Qiong Wang , Jun Ren , Wen-Jing Xiong , Fang Lu , Jian-Ping Liu
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: E-ISSN: 1932-6203 ; DOI: 10.1371/journal.pone.0110560
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: doaj_soai_doaj_org_article_a47eecb907ac447ba739251285b995de
title: Chinese proprietary herbal medicine listed in 'China national essential drug list' for common cold: a systematic literature review
format: Article
creator:
  • Wei Chen
  • George Lewith
  • Li-Qiong Wang
  • Jun Ren
  • Wen-Jing Xiong
  • Fang Lu
  • Jian-Ping Liu
subjects:
  • Sciences (General)
ispartof: PLoS ONE, 01 January 2014, Vol.9(10), p.e110560
description: Chinese proprietary herbal medicines (CPHMs) have long history in China for the treatment of common cold, and lots of them have been listed in the 'China national essential drug list' by the Chinese Ministry of Health. The aim of this review is to provide a well-round clinical evidence assessment on the potential benefits and harms of CPHMs for common cold based on a systematic literature search to justify their clinical use and recommendation.We searched CENTRAL, MEDLINE, EMBASE, SinoMed, CNKI, VIP, China Important Conference Papers Database, China Dissertation Database, and online clinical trial registry websites from their inception to 31 March 2013 for clinical studies of CPHMs listed in the 'China national essential drug list' for common cold. There was no restriction on study design.A total of 33 CPHMs were listed in 'China national essential drug list 2012' for the treatment of common cold but only 7 had supportive clinical evidences. A total of 6 randomised controlled trials (RCTs) and 7 case series (CSs) were included; no other study design was identified. All studies were conducted in China and published in Chinese between 1995 and 2012. All included studies had poor study design and methodological quality, and were graded as very low quality.The use of CPHMs for common cold is not supported by robust evidence. Further rigorous well designed placebo-controlled, randomized trials are needed to substantiate the clinical claims made for CPHMs.
language: eng
source:
identifier: E-ISSN: 1932-6203 ; DOI: 10.1371/journal.pone.0110560
fulltext: fulltext_linktorsrc
issn:
  • 1932-6203
  • 19326203
url: Link


@attributes
ID1389548320
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordidoai_doaj_org_article_a47eecb907ac447ba739251285b995de
sourceiddoaj_s
recordidTN_doaj_soai_doaj_org_article_a47eecb907ac447ba739251285b995de
sourcesystemOther
dbidDOA
pqid1614379712
galeid418139305
display
typearticle
titleChinese proprietary herbal medicine listed in 'China national essential drug list' for common cold: a systematic literature review
creatorWei Chen ; George Lewith ; Li-Qiong Wang ; Jun Ren ; Wen-Jing Xiong ; Fang Lu ; Jian-Ping Liu
ispartofPLoS ONE, 01 January 2014, Vol.9(10), p.e110560
identifierE-ISSN: 1932-6203 ; DOI: 10.1371/journal.pone.0110560
subjectSciences (General)
descriptionChinese proprietary herbal medicines (CPHMs) have long history in China for the treatment of common cold, and lots of them have been listed in the 'China national essential drug list' by the Chinese Ministry of Health. The aim of this review is to provide a well-round clinical evidence assessment on the potential benefits and harms of CPHMs for common cold based on a systematic literature search to justify their clinical use and recommendation.We searched CENTRAL, MEDLINE, EMBASE, SinoMed, CNKI, VIP, China Important Conference Papers Database, China Dissertation Database, and online clinical trial registry websites from their inception to 31 March 2013 for clinical studies of CPHMs listed in the 'China national essential drug list' for common cold. There was no restriction on study design.A total of 33 CPHMs were listed in 'China national essential drug list 2012' for the treatment of common cold but only 7 had supportive clinical evidences. A total of 6 randomised controlled trials (RCTs) and 7 case series (CSs) were included; no other study design was identified. All studies were conducted in China and published in Chinese between 1995 and 2012. All included studies had poor study design and methodological quality, and were graded as very low quality.The use of CPHMs for common cold is not supported by robust evidence. Further rigorous well designed placebo-controlled, randomized trials are needed to substantiate the clinical claims made for CPHMs.
languageeng
oafree_for_read
source
version7
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
linktorsrc$$Uhttps://doaj.org/article/a47eecb907ac447ba739251285b995de$$EView_full_text_in_DOAJ
search
creatorcontrib
0Wei Chen
1George Lewith
2Li-Qiong Wang
3Jun Ren
4Wen-Jing Xiong
5Fang Lu
6Jian-Ping Liu
titleChinese proprietary herbal medicine listed in 'China national essential drug list' for common cold: a systematic literature review
description

Chinese proprietary herbal medicines (CPHMs) have long history in China for the treatment of common cold, and lots of them have been listed in the 'China national essential drug list' by the Chinese Ministry of Health. The aim of this review is to provide a well-round clinical evidence assessment on the potential benefits and harms of CPHMs for common cold based on a systematic literature search to justify their clinical use and recommendation.We searched CENTRAL, MEDLINE, EMBASE, SinoMed, CNKI, VIP, China Important Conference Papers Database, China Dissertation Database, and online clinical trial registry websites from their inception to 31 March 2013 for clinical studies of CPHMs listed in the 'China national essential drug list' for common cold. There was no restriction on study design.A total of 33 CPHMs were listed in 'China national essential drug list 2012' for the treatment of common cold but only 7 had supportive clinical evidences. A total of 6 randomised controlled trials (RCTs) and 7 case series (CSs) were included; no other study design was identified. All studies were conducted in China and published in Chinese between 1995 and 2012. All included studies had poor study design and methodological quality, and were graded as very low quality.The use of CPHMs for common cold is not supported by robust evidence. Further rigorous well designed placebo-controlled, randomized trials are needed to substantiate the clinical claims made for CPHMs.

subjectSciences (General)
general
0English
1Public Library of Science (PLoS)
210.1371/journal.pone.0110560
3Directory of Open Access Journals (DOAJ)
sourceiddoaj_s
recordiddoaj_soai_doaj_org_article_a47eecb907ac447ba739251285b995de
issn
01932-6203
119326203
rsrctypearticle
creationdate2014
addtitlePLoS ONE
searchscope
0doaj_full
1doaj1
scope
0doaj_full
1doaj1
lsr45$$EView_full_text_in_DOAJ
tmp01Directory of Open Access Journals (DOAJ)
tmp02DOA
startdate20140101
enddate20140101
lsr40PLoS ONE, 01 January 2014, Vol.9 (10), p.e110560
doi10.1371/journal.pone.0110560
citationpf e110560 vol 9 issue 10
lsr30VSR-Enriched:[pqid, pages, galeid]
sort
titleChinese proprietary herbal medicine listed in 'China national essential drug list' for common cold: a systematic literature review
authorWei Chen ; George Lewith ; Li-Qiong Wang ; Jun Ren ; Wen-Jing Xiong ; Fang Lu ; Jian-Ping Liu
creationdate20140101
lso0120140101
facets
frbrgroupid8999787846429421798
frbrtype5
newrecords20190714
languageeng
topicSciences (General)
collectionDirectory of Open Access Journals (DOAJ)
prefilterarticles
rsrctypearticles
creatorcontrib
0Wei Chen
1George Lewith
2Li-Qiong Wang
3Jun Ren
4Wen-Jing Xiong
5Fang Lu
6Jian-Ping Liu
jtitlePLoS ONE
creationdate2014
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext_linktorsrc
addata
au
0Wei Chen
1George Lewith
2Li-Qiong Wang
3Jun Ren
4Wen-Jing Xiong
5Fang Lu
6Jian-Ping Liu
atitleChinese proprietary herbal medicine listed in 'China national essential drug list' for common cold: a systematic literature review
jtitlePLoS ONE
risdate20140101
volume9
issue10
spagee110560
eissn1932-6203
formatjournal
genrearticle
ristypeJOUR
abstract

Chinese proprietary herbal medicines (CPHMs) have long history in China for the treatment of common cold, and lots of them have been listed in the 'China national essential drug list' by the Chinese Ministry of Health. The aim of this review is to provide a well-round clinical evidence assessment on the potential benefits and harms of CPHMs for common cold based on a systematic literature search to justify their clinical use and recommendation.We searched CENTRAL, MEDLINE, EMBASE, SinoMed, CNKI, VIP, China Important Conference Papers Database, China Dissertation Database, and online clinical trial registry websites from their inception to 31 March 2013 for clinical studies of CPHMs listed in the 'China national essential drug list' for common cold. There was no restriction on study design.A total of 33 CPHMs were listed in 'China national essential drug list 2012' for the treatment of common cold but only 7 had supportive clinical evidences. A total of 6 randomised controlled trials (RCTs) and 7 case series (CSs) were included; no other study design was identified. All studies were conducted in China and published in Chinese between 1995 and 2012. All included studies had poor study design and methodological quality, and were graded as very low quality.The use of CPHMs for common cold is not supported by robust evidence. Further rigorous well designed placebo-controlled, randomized trials are needed to substantiate the clinical claims made for CPHMs.

pubPublic Library of Science (PLoS)
doi10.1371/journal.pone.0110560
urlhttps://doaj.org/article/a47eecb907ac447ba739251285b995de
lad01PLoS ONE
oafree_for_read
pagese110560
date2014-01-01